Search results
Results from the WOW.Com Content Network
Mayo Clinic Proceedings is a monthly peer-reviewed medical journal published by Elsevier and sponsored by the Mayo Clinic. It covers the field of general internal medicine. The journal was established in 1926 as the Proceedings of the Staff Meetings of the Mayo Clinic and obtained its current name in 1964.
In contrast, the prothrombin time (PT), another non-specific coagulation test, is normally unaffected by lupus anticoagulant. Nevertheless, falsely increased PT has been reported, likely by lupus anticoagulant interfering with the phospholipid component of the PT reagent, particularly when using recombinant tissue factor and purified phospholipids.
A coagulation screen is a combination of screening laboratory tests, designed to provide rapid non-specific information, which allows an initial broad categorization of haemostatic problems. [ 1 ] Process
The prothrombin time (PT) – along with its derived measures of prothrombin ratio (PR) and international normalized ratio (INR) – is an assay for evaluating the extrinsic pathway and common pathway of coagulation. This blood test is also called protime INR and PT/INR.
A recent patent review has shown that the general consensus among researchers is that allosteric inhibitors may provide a more regulatable anticoagulant. [3] Some of the allosteric inhibitors discovered include DNA aptamers, [ 3 ] benzofuran dimers, [ 4 ] benzofuran trimers, [ 5 ] as well as polymeric lignins. [ 6 ]
Liver function tests (LFTs or LFs), also referred to as a hepatic panel or liver panel, are groups of blood tests that provide information about the state of a patient's liver. [1] These tests include prothrombin time (PT/INR), activated partial thromboplastin time (aPTT), albumin , bilirubin (direct and indirect), and others.
The Mayo Clinic diet, a program that adheres to this notion, was developed by medical professionals based on scientific research, so you can trust that this program is based on science, and not ...
Skeletal formula of tipifarnib (R115777), a farnesyltransferase inhibitor that reached Phase III clinical trials. The farnesyltransferase inhibitors (FTIs) are a class of experimental cancer drugs that target protein farnesyltransferase with the downstream effect of preventing the proper functioning of the Ras (protein), which is commonly abnormally active in cancer.